Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
aim, amplification, BEACON, BRAF, Brexit, cap, cetuximab, CMC, cohort, colorectal, Conformit, cutoff, Cyclin, DNA, effectuated, encorafenib, Enhancing, enrichment, exhibiting, gap, gastrointestinal, gemcitabine, Intelligence, intracellular, IRA, mCRC, opposed, outpace, overexpression, pancreatic, PK, quarantine, rebate, regression, Rescue, Society, software, timeline, Tissue, Untied
Removed:
abemaciclib, agnostic, Brain, breast, cell, center, concurred, Dana, designated, Eli, epidermal, epithelial, estrogen, Farber, fourth, glioblastoma, immunotherapy, intention, Ivy, lab, Lilly, lung, multiforme, mutant, NaN, NSCLC, palbociclib, poly, polymerase, postpone, principle, prioritized, proposal, receptor, resume, rotational, SERD, stay, subsidiary, Taxpayer, temporary, triple, voucher
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view